Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
暂无分享,去创建一个
J. Borén | M. Taskinen | G. Watts | B. Nordestgaard | E. Fisher | P. Amarenco | O. Descamps | P. Kovanen | Ž. Reiner | L. Tokgözoğlu | F. Andreotti | A. Catapano | L. Masana | H. Ginsberg | A. Tybjærg‐Hansen | J. Kuivenhoven | M. J. Chapman | K. Ray | P. Lesnik | M. Chapman
[1] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.
[2] B. Lask,et al. Implications for Treatment , 2011 .
[3] R. Krauss,et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. , 2011, Clinical chemistry.
[4] M. Clearfield. Combination Lipid Therapy in Type 2 Diabetes , 2011, Current atherosclerosis reports.
[5] P. Nilsson,et al. Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register , 2011, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[6] Robert L Wilensky,et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.
[7] G. Watts,et al. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies , 2011, Expert opinion on pharmacotherapy.
[8] B. Gersh. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial , 2011 .
[9] V. Gebski,et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study , 2011, Diabetologia.
[10] Christopher P Cannon,et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. , 2010, The New England journal of medicine.
[11] C. Stehouwer,et al. Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus , 2010, Current opinion in lipidology.
[12] J. Geleijnse,et al. n-3 fatty acids and cardiovascular events after myocardial infarction. , 2010, The New England journal of medicine.
[13] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[14] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[15] M. Ai,et al. [Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.
[16] J. Borén,et al. Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.
[17] Rena R Wing,et al. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. , 2010, Archives of internal medicine.
[18] P. Barter,et al. Effects of High-Density Lipoproteins on Pancreatic &bgr;-Cell Insulin Secretion , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[19] J. Kastelein,et al. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? , 2010, Journal of Lipid Research.
[20] V. Salomaa,et al. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia , 2010, Nature Genetics.
[21] G. Getz,et al. High-density lipoprotein function in regulating insulin secretion: possible relevance to metabolic syndrome. , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[22] Tanya M. Teslovich,et al. Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.
[23] P. Libby,et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial , 2010, The Lancet.
[24] Walter T Ambrosius,et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.
[25] E. Fisher. GPIHBP1: lipoprotein lipase's ticket to ride. , 2010, Cell metabolism.
[26] G. Assmann,et al. Non-LDL-related dyslipidaemia and coronary risk: a case-control study , 2010, Diabetes & vascular disease research.
[27] A. Tall,et al. Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[28] A. Keech,et al. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes , 2010, Diabetologia.
[29] Pierre Amarenco,et al. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. , 2010, Atherosclerosis.
[30] P. Giral,et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. , 2010, Pharmacology & therapeutics.
[31] D. Grobbee,et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.
[32] Jennifer G. Robinson,et al. Dalcetrapib: a review of Phase II data , 2010, Expert opinion on investigational drugs.
[33] J. Danesh,et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.
[34] J. Paolini,et al. Efficacy and safety of extended‐release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia , 2010, International journal of clinical practice.
[35] P. Barter,et al. Evidence That Niacin Inhibits Acute Vascular Inflammation and Improves Endothelial Dysfunction Independent of Changes in Plasma Lipids , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[36] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.
[37] E. Wijsman,et al. Linkage and association analyses identify a candidate region for apoB level on chromosome 4q32.3 in FCHL families , 2010, Human Genetics.
[38] Ž. Reiner. Combined therapy in the treatment of dyslipidemia , 2010, Fundamental & Clinical Pharmacology.
[39] David W. Williamson,et al. Polymorphisms in the hepatic lipase gene affect plasma HDL-cholesterol levels in a Turkish population[S] , 2010, Journal of Lipid Research.
[40] R. Frikke-Schmidt. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. , 2010, Atherosclerosis.
[41] Jennifer G. Robinson,et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial , 2010, European heart journal.
[42] Costantina Manes,et al. Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy , 2010, Circulation.
[43] S. Young,et al. Integrative Physiology/Experimental Medicine Chylomicronemia Elicits Atherosclerosis in Mice—Brief Report , 2009 .
[44] A. Kontush,et al. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors , 2009, European heart journal.
[45] R. Havel. Triglyceride-rich lipoproteins and plasma lipid transport. , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[46] V. Preedy,et al. Randomized Controlled Trial , 2010 .
[47] G. Moneta,et al. Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .
[48] J. Shaw,et al. Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.
[49] Michael Miller,et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. , 2009, The New England journal of medicine.
[50] D. Sviridov,et al. Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux , 2009, Circulation.
[51] J. Danesh,et al. Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.
[52] M. Robson,et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. , 2009, Journal of the American College of Cardiology.
[53] P. Barter,et al. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. , 2009, Archives of internal medicine.
[54] M. Taskinen,et al. Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes , 2009, Diabetes Care.
[55] B. Nordestgaard. Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere , 2009, Current opinion in lipidology.
[56] D. Panagiotakos,et al. Responses of Blood Lipids to Aerobic, Resistance, and Combined Aerobic With Resistance Exercise Training: A Systematic Review of Current Evidence , 2009, Angiology.
[57] A. von Eckardstein,et al. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. , 2009, Endocrinology.
[58] Robert Dufour,et al. Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations , 2009 .
[59] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[60] S. Grundy,et al. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. , 2009, The American journal of cardiology.
[61] G. Watts,et al. Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome , 2009, Diabetes Care.
[62] M. Hennerici,et al. Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial , 2009, Stroke.
[63] A. Keech,et al. Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate , 2009, Arteriosclerosis, Thrombosis and Vascular Biology.
[64] R. Walzem,et al. Apolipoprotein A-I and Its Role in Lymphocyte Cholesterol Homeostasis and Autoimmunity , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[65] A. von Eckardstein,et al. High-Density Lipoprotein Transport Through Aortic Endothelial Cells Involves Scavenger Receptor BI and ATP-Binding Cassette Transporter G1 , 2009, Circulation research.
[66] T. Valle,et al. Ten-Year Mortality and Cardiovascular Morbidity in the Finnish Diabetes Prevention Study—Secondary Analysis of the Randomized Trial , 2009, PloS one.
[67] W. Loging,et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. , 2009, Endocrinology.
[68] F. Magkos. Basal very low-density lipoprotein metabolism in response to exercise: mechanisms of hypotriacylglycerolemia. , 2009, Progress in lipid research.
[69] K. Kotseva,et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[70] B. Nordestgaard,et al. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. , 2009, The Journal of clinical endocrinology and metabolism.
[71] D. Sviridov,et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. , 2009, Journal of the American College of Cardiology.
[72] Gordon H Guyatt,et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis , 2009, BMJ : British Medical Journal.
[73] N. Fournier,et al. Torcetrapib Differentially Modulates the Biological Activities of HDL2 and HDL3 Particles in the Reverse Cholesterol Transport Pathway , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[74] Robert A. Hegele,et al. Plasma lipoproteins: genetic influences and clinical implications , 2009, Nature Reviews Genetics.
[75] M. Fiatarone Singh,et al. Adaptations to exercise training within skeletal muscle in adults with type 2 diabetes or impaired glucose tolerance: a systematic review , 2009, Diabetes/metabolism research and reviews.
[76] Executive Summary: Standards of Medical Care in Diabetes—2009 , 2009, Diabetes Care.
[77] A. Keech,et al. Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome , 2008, Diabetes Care.
[78] M. Taskinen,et al. Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: FIELD Helsinki Substudy Renal effects of fenofibrate in type 2 diabetes , 2009 .
[79] C. Ballantyne,et al. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia , 2009 .
[80] G. Kelley,et al. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. , 2009, Preventive medicine.
[81] A. Keech,et al. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. , 2008, Journal of the American College of Cardiology.
[82] B. Stamford,et al. Smoking and smoking cessation -- the relationship between cardiovascular disease and lipoprotein metabolism: a review. , 2008, Atherosclerosis.
[83] D. Sviridov,et al. Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque , 2008, Circulation research.
[84] D. Sviridov,et al. High-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[85] G. Watts,et al. Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism. , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[86] B. Nordestgaard,et al. Nonfasting triglycerides and risk of ischemic stroke in the general population. , 2008, JAMA.
[87] L. Sidossis,et al. Acute exercise-induced changes in basal VLDL-triglyceride kinetics leading to hypotriglyceridemia manifest more readily after resistance than endurance exercise. , 2008, Journal of applied physiology.
[88] G. Watts,et al. Atorvastatin and Fenofibrate Have Comparable Effects on VLDL–Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[89] A. Zwinderman,et al. High HDL cholesterol does not protect against coronary artery disease when associated with combined cholesteryl ester transfer protein and hepatic lipase gene variants. , 2008, Atherosclerosis.
[90] A. Lichtenstein,et al. Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[91] F. Sacks,et al. Dietary monounsaturated fat activates metabolic pathways for triglyceride-rich lipoproteins that involve apolipoproteins E and C-III. , 2008, The American journal of clinical nutrition.
[92] J. Danesh,et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. , 2008, JAMA.
[93] Anders G. Olsson,et al. Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment , 2008, Circulation.
[94] J. Ehrhart,et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone , 2008, British journal of pharmacology.
[95] Børge G Nordestgaard,et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.
[96] J. Mckenney,et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). , 2008, The American journal of cardiology.
[97] J. Dora,et al. Standards of Medical Care in Diabetes—2008 , 2008, Diabetes Care.
[98] V. Kamanna,et al. Mechanism of action of niacin. , 2008, The American journal of cardiology.
[99] K. Frayn,et al. Leukocyte Activation by Triglyceride-Rich Lipoproteins , 2008, Arteriosclerosis, thrombosis, and vascular biology.
[100] Curt D. Furberg,et al. Lipoprotein Management in Patients With Cardiometabolic Risk , 2008, Diabetes Care.
[101] A. Tighe,et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications , 2008, Expert review of cardiovascular therapy.
[102] Christopher P Cannon,et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. , 2008, Journal of the American College of Cardiology.
[103] R. Collins,et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease , 2008, Nature Genetics.
[104] Dolores Corella,et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.
[105] S. Offermanns,et al. Nicotinic acid: pharmacological effects and mechanisms of action. , 2008, Annual review of pharmacology and toxicology.
[106] S. Allender,et al. European cardiovascular disease statistics , 2008 .
[107] R. Holman,et al. Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial , 2008, Diabetologia.
[108] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.
[109] P. Mitchell,et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.
[110] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[111] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invit , 2007, European heart journal.
[112] A. Gotto,et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2007, The New England journal of medicine.
[113] J. Brunzell,et al. Clinical practice. Hypertriglyceridemia. , 2007, The New England journal of medicine.
[114] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invit , 2007, European heart journal.
[115] Ling Liu,et al. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase Published, JLR Papers in Press, May 13, 2007. , 2007, Journal of Lipid Research.
[116] P. Grant. Diabetes mellitus as a prothrombotic condition , 2007, Journal of internal medicine.
[117] B. Nordestgaard,et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.
[118] J. Mckenney,et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). , 2007, Atherosclerosis.
[119] G. O'neill,et al. Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1 , 2007, Clinical pharmacology and therapeutics.
[120] Y. Ohashi,et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. , 2007, Archives of internal medicine.
[121] J. Ornato,et al. Implication of the new low-density lipoprotein goals in dyslipidemia management of patients with acute coronary syndrome. , 2007, Mayo Clinic proceedings.
[122] C. Shear,et al. Inhibition of Cholesteryl Ester Transfer Protein by Torcetrapib Modestly Increases Macrophage Cholesterol Efflux to HDL , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[123] Colin Berry,et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. , 2007, JAMA.
[124] Y. Matsuzawa,et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.
[125] J. Mckenney,et al. Safety considerations with fibrate therapy. , 2007, The American journal of cardiology.
[126] G. Bray,et al. Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes , 2007, Diabetes Care.
[127] F. Hu,et al. Physical Activity of Moderate Intensity and Risk of Type 2 Diabetes , 2007, Diabetes Care.
[128] S. Simon,et al. Triglyceride-Rich Lipoproteins Prime Aortic Endothelium for an Enhanced Inflammatory Response to Tumor Necrosis Factor-α , 2007, Circulation research.
[129] Paul Schoenhagen,et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. , 2007, JAMA.
[130] A. Leaf. Omega-3 fatty acids and prevention of arrhythmias , 2007, Current opinion in lipidology.
[131] Peter Lindgren,et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .
[132] M. Laakso,et al. Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases: Executive Summary , 2007 .
[133] B. G. Brown,et al. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials , 2006, Current opinion in lipidology.
[134] G. Su,et al. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. , 2006, Clinical chemistry.
[135] Allen J. Taylor,et al. The effect of 24 months of combination statin and extended-release niacin on carotid intima‐media thickness: ARBITER 3* , 2006, Current medical research and opinion.
[136] E. Braunwald,et al. Coronary heart disease Acute coronary syndromes and diabetes : is intensive lipid lowering beneficial ? Results of the PROVE IT-TIMI 22 trial , 2006 .
[137] H. Brewer,et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation. , 2006, The American journal of cardiology.
[138] S. Grundy,et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study , 2006, The Lancet.
[139] A. Kontush,et al. Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis , 2006, Pharmacological Reviews.
[140] Yao-min Hu,et al. A systematic review and meta-analysis of the relationship between lipoprotein lipase Asn291Ser variant and diseases Published, JLR Papers in Press, June 1, 2006. , 2006, Journal of Lipid Research.
[141] P. Barter,et al. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. , 2006, Journal of the American College of Cardiology.
[142] G. Watts,et al. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. , 2006, The American journal of clinical nutrition.
[143] J. Griffin,et al. Endothelial and antithrombotic actions of HDL. , 2006, Circulation research.
[144] P. Barter,et al. High-Density Lipoproteins Enhance Progenitor-Mediated Endothelium Repair in Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[145] C. Oktenli,et al. Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey , 2006, BMC public health.
[146] C. Furberg,et al. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). , 2006, The American journal of cardiology.
[147] C. Roberts,et al. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. , 2004, Journal of applied physiology.
[148] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.
[149] B. Rosner,et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. , 2005, JAMA.
[150] E. Braunwald,et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.
[151] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[152] M. Quon,et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. , 2005, Journal of the American College of Cardiology.
[153] M. Taskinen. Type 2 diabetes as a lipid disorder. , 2005, Current molecular medicine.
[154] M. Ezekowitz,et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. , 2005, European heart journal.
[155] S. Grundy,et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). , 2005, The American journal of cardiology.
[156] A. Gotto,et al. A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events , 2005, Annals of Internal Medicine.
[157] C. Furberg,et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). , 2005, The American journal of cardiology.
[158] G. Mancia,et al. Acute Effect of High-Fat Meal on Endothelial Function in Moderately Dyslipidemic Subjects , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[159] D. Gordon,et al. High-Density Lipoprotein Cholesterol and Cardiovascular Disease , 2005 .
[160] Jeannie K. Lee,et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.
[161] G. Derosa,et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. , 2004, Clinical therapeutics.
[162] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[163] G. Dallinga-Thie,et al. Elevated Remnant-Like Particle Cholesterol Concentration: A Characteristic Feature of the Atherogenic Lipoprotein Phenotype , 2004, Circulation.
[164] C. Scriver,et al. The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.
[165] Paul Schoenhagen,et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.
[166] T. Fukui,et al. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. , 2003, Preventive medicine.
[167] B. Nordestgaard,et al. Hepatic lipase mutations,elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study. , 2003, Journal of the American College of Cardiology.
[168] R. Mensink,et al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. , 2003, The American journal of clinical nutrition.
[169] G. Watts,et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. , 2003, Diabetes.
[170] W. Harris,et al. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance Published, JLR Papers in Press, December 1, 2002. DOI 10.1194/jlr.M200282-JLR200 , 2003, Journal of Lipid Research.
[171] V. Fuster,et al. Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity , 2003, Circulation.
[172] H. Ginsberg. New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism , 2002, Circulation.
[173] S. Grundy,et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. , 2002, Archives of internal medicine.
[174] V. Athyros,et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. , 2002, Diabetes care.
[175] C. Di Mario,et al. Recombinant Apolipoprotein A-IMilano Infusion Into Rabbit Carotid Artery Rapidly Removes Lipid From Fatty Streaks , 2002, Circulation research.
[176] F. Ruschitzka,et al. High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men , 2002, Circulation.
[177] E. Bolson,et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.
[178] J. Wittes,et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.
[179] Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.
[180] D. Hunninghake,et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. , 2000, JAMA.
[181] Bezafibrate Infarction Prevention study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.
[182] P. Grant,et al. Plasminogen-activator inhibitor type 1 and coronary artery disease. , 2000, The New England journal of medicine.
[183] B. Guy-grand,et al. Evidence for a cholesteryl ester donor activity of LDL particles during alimentary lipemia in normolipidemic subjects. , 1999, Atherosclerosis.
[184] GISSI-Prevenzione Investigators,et al. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.
[185] Roberto Marchioli,et al. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .
[186] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[187] B. Nordestgaard,et al. Lipoprotein Lipase Mutations, Plasma Lipids and Lipoproteins, and Risk of Ischemic Heart Disease A Meta-Analysis , 1999 .
[188] A. Tybjaerg-hansen,et al. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. , 1999, Circulation.
[189] José A Fernández,et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. , 1999, The Journal of clinical investigation.
[190] 武井泉,et al. United Kingdom Prospective Diabetes Study (UKPDS) , 1999 .
[191] S. Proctor,et al. Retention of fluorescent‐labelled chylomicron remnants within the intima of the arterial wall — evidence that plaque cholesterol may be derived from post‐prandial lipoproteins , 1998, European journal of clinical investigation.
[192] G. Assmann,et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[193] G. Thorgeirsson,et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) , 1998, Circulation.
[194] A. Nicolaides,et al. Cardiovascular Outcomes in Type 2 Diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study , 1998, Diabetes Care.
[195] R. Holman,et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.
[196] K. Mann,et al. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[197] M. Nieminen,et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.
[198] W. Mack,et al. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[199] J. Hokanson. Lipoprotein lipase gene variants and risk of coronary disease: a quantitative analysis of population-based studies , 1997, International journal of clinical & laboratory research.
[200] B. Nordestgaard,et al. Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. , 1996, Stroke.
[201] M J Davies,et al. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. , 1996, Circulation.
[202] M. Hayden,et al. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. , 1996, The New England journal of medicine.
[203] E. Bruckert,et al. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[204] J. Hokanson,et al. Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.
[205] A. Hamsten,et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients , 1996, The Lancet.
[206] V. Fuster,et al. Coronary plaque disruption. , 1995, Circulation.
[207] K. Williams,et al. The response-to-retention hypothesis of early atherogenesis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[208] R. Mahley,et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. , 1995, Journal of lipid research.
[209] R. Havel,et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[210] R. Epand,et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.
[211] P. Touboul,et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease , 1994, The Lancet.
[212] W. Willett,et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. , 1993, The New England journal of medicine.
[213] I. Goldberg,et al. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. , 1993, The Journal of clinical investigation.
[214] X. Chen,et al. N-3 fatty acids stimulate intracellular degradation of apoprotein B in rat hepatocytes. , 1993, The Journal of clinical investigation.
[215] A. Dattilo,et al. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. , 1992, The American journal of clinical nutrition.
[216] B. Lewis,et al. Effects on Coronary Artery Disease of Lipid-Lowering Diet, or Diet Plus Cholestyramine, in the St. Thomasʼ Artherosclerosis Regression Study (STARS) , 1992 .
[217] G. Schuler,et al. Regular Physical Exercise and Low‐Fat Diet: Effects on Progression of Coronary Artery Disease , 1992, Circulation.
[218] G. Reaven,et al. Insulin resistance and cigarette smoking , 1992, The Lancet.
[219] L. Tenkanen,et al. Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study , 1992 .
[220] G. Watts,et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) , 1992, The Lancet.
[221] Vesa Manninen,et al. Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for Treatment , 1992, Circulation.
[222] R. Krauss,et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI , 1991, Nature.
[223] M. B. Katan,et al. Increased removal of remnants of triglyceride‐rich lipoproteins on a diet rich in polyunsaturated fatty acids , 1991, European journal of clinical investigation.
[224] M. Austin. Plasma triglyceride and coronary heart disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[225] M J Malloy,et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.
[226] J J Albers,et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.
[227] K. Gould,et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial , 1990, The Lancet.
[228] V. Fuster,et al. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.
[229] D R Jacobs,et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. , 1990, American journal of epidemiology.
[230] P. Elwood,et al. EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART) , 1989, The Lancet.
[231] D. Gordon,et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. , 1989, Circulation.
[232] D. B. Zilversmit,et al. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. , 1988, Journal of lipid research.
[233] B. Nordestgaard,et al. Reduced Atherogenesis in Cholesterol‐fed Diabetic Rabbits: Giant Lipoproteins Do Not Enter the Arterial Wall , 1988, Arteriosclerosis.
[234] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.
[235] D H Blankenhorn,et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. , 1987, JAMA.
[236] S. Wong,et al. Eicosapentaenoic acid inhibits the secretion of triacylglycerol and of apoprotein B and the binding of LDL in Hep G2 cells. , 1987, Atherosclerosis.
[237] J. Stamler,et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.
[238] H. Sewell,et al. CYTOCHROME P-450 IMMUNOLOCALISATION IN HUMAN LIVER , 1986, The Lancet.
[239] G. Schonfeld,et al. Aortic accumulation and plasma clearance of beta-VLDL and HDL: effects of diet-induced hypercholesterolemia in rabbits. , 1985, Journal of lipid research.
[240] R. Boston,et al. Suppression by diets rich in fish oil of very low density lipoprotein production in man. , 1984, The Journal of clinical investigation.
[241] S. Grundy,et al. Effects of alcohol on plasma lipoproteins and cholesterol and triglyceride metabolism in man. , 1984, Journal of lipid research.
[242] R. Mahley,et al. Foam Cells in Explants of Atherosclerotic Rabbit Aortas Have Receptors for β‐Very Low Density Low Density Lipoproteins and Modified Low Density Lipoproteins , 1983, Arteriosclerosis.
[243] I. Holme,et al. EFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE Report from the Oslo Study Group of a Randomised Trial in Healthy Men , 1981, The Lancet.
[244] I. Hjermann,et al. EFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE , 1981 .
[245] R. Mahley,et al. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. , 1980, The Journal of biological chemistry.
[246] D. B. Zilversmit. Atherogenesis: a postprandial phenomenon. , 1979, Circulation.
[247] M. Karvonen,et al. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. , 1979, British heart journal.
[248] D. Grafnetter,et al. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators. , 1978, British heart journal.
[249] S. Rössner,et al. Coronary Drug Project Research Group. , 1978, Atherosclerosis.
[250] J. Stamler. Clofibrate and niacin in coronary heart disease. , 1975, JAMA.
[251] G. Reaven,et al. Moderate ethanol ingestion and plasma triglyceride levels. A study in normal and hypertriglyceridemic persons. , 1974, Annals of internal medicine.
[252] A. Motulsky,et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. , 1973, The Journal of clinical investigation.
[253] Joseph L. Goldstein,et al. Hyperlipidemia in Coronary Heart Disease , 1973 .
[254] E. B. Smith,et al. The microdissection of large atherosclerotic plaques to give morphologically and topographically defined fractions for analysis. 1. The lipids in the isolated fractions. , 1972, Atherosclerosis.
[255] E. B. Smith,et al. The microdissection of large atherosclerotic plaques to give morphologically and topographically defined fractions for analysis. 2. Studies on "nile blue" cells. , 1972, Atherosclerosis.